Created in 2012, LAMIVAC (International Joint Research Laboratory for Vaccinology) is administered by two institutions that have been partners for over 40 years: AMP (Agence de Médecine Préventive) and the Muraz Center in Bobo-Dioulasso, Burkina Faso.
Set up as an economic interest grouping (EIG), LAMIVAC aims to consolidate, rapidly mobilize and effectively manage a range of vaccinology skills to carry out joint projects using a common platform (human skills, laboratories, equipment, computer resources, documentary resources, etc.).
LAMIVAC operates in priority areas such as:
- New vaccine introduction in developing countries
- Epidemiological studies on distribution and burden of disease with implementation of enhanced microbiological monitoring (sero-epidemiological studies, microbiological variability studies, studies on the introduction of new diagnostic methods and technology transfers, and research on resistance to treatment)
- Vaccine safety and monitoring for adverse effects: tolerance and pharmacovigilance
- Immunogenicity studies specific to the use of already-licensed vaccines
- Immunization strategy studies including efficacy studies, vaccine schedule studies (compatibility with the Expanded Program on Immunization (EPI)), and introduction studies (acceptability, supply chain, training, logistics specificities, coverage)
- Impact studies on carriage and transmission interruption
- Socio-economic and anthropological studies for a better understanding of vaccine strategies
- Training in applied research in the field and supplementary areas of vaccinology